Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q3 2026
Rhythm Pharmaceuticals (RYTM) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Rhythm Pharmaceuticals (RYTM) reported revenue of $92.1M for the third quarter 2026 (Q3 2026), +80% from a year earlier and +29% from the quarter before. Operating margin was -42.6%, net loss $41.4M (44.9% of revenue).
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $92.1M | +29% | +80% |
| Operating profit | −$39.3M | — | — |
| Net earnings | −$41.4M | — | — |
| Operating cash flow | −$3.1M | — | — |
What changed
Revenue was $92.1M in Q3 2026, up 80% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $39.3M, an operating margin of -42.6%. Total costs grew 26% against revenue growth of 80%. The fastest-growing cost line was Cost of revenue (+121%). The quarter ended with a net loss of $41.4M, narrower than the previous quarter's $49.3M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $25.0M of share-based compensation. Working capital and other items added $13.3M.
Questions
What was Rhythm Pharmaceuticals' revenue in the third quarter 2026?
Rhythm Pharmaceuticals (RYTM) reported revenue of $92.1M for the third quarter 2026 (Q3 2026), +80% from a year earlier and +29% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $39.3M (-42.6% of revenue) and net loss $41.4M.